[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"pulmonary-alveolar-proteinosis\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:pulmonary-alveolar-proteinosis":94},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,40,66],{"id":9,"slug":4,"hasResults":10,"nctId":11,"briefTitle":12,"officialTitle":12,"acronym":4,"eligibilityCriteria":13,"healthyVolunteers":10,"sex":14,"minAge":4,"maxAge":4,"enrollmentInfo":15,"targetDuration":18,"studyType":19,"phases":4,"briefSummary":20,"conditions":21,"keywords":23,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":28,"lastUpdatePostDateStruct":29,"startDateStruct":32,"completionDateStruct":34,"leadSponsor":36,"locationsCount":39},"100244533",false,"NCT02461615","A National Registry For Pulmonary Alveolar Proteinosis","Inclusion Criteria for Part A and Part B:\n\n* Written informed consent and assent, if applicable\n\nInclusion Criteria for Part A (Cross Sectional Study of PAP Syndrome)\n\n* History of chest computed tomogram or chest radiograph findings compatible with PAP\n* History of diagnosis of PAP made by at least one of the following methods:\n\n  * Positive (Abnormal) serum GMAb test -OR-\n  * Lung biopsy clearly documenting the presence of PAP of any type or degree -OR-\n  * Bronchoalveolar lavage cytology compatible with PAP -OR-\n  * Recessive or compound mutations in genes known to cause PAP, i.e. GM-CSF receptor α or β chain, GM-CSF, surfactant protein B or C or ABCA3, ABCG1, ABCA1, TTF1\n\nInclusion Criteria For Part B (Longitudinal \\& PRO Survey Study of autoimmune PAP Patients)\n\n* Diagnosis of autoimmune PAP as indicated by:\n\n  * Positive (Abnormal) Serum GMAb Test -AND-\n  * History of chest CT or x-rays findings compatible with PAP -OR-\n  * Lung biopsy clearly documenting the presence of PAP of any type or degree -OR-\n  * Bronchoalveolar lavage cytology compatible with PAP\n\nExclusion Criteria or Part A and Part B:\n\n* Individuals who have a serious medical illness that, in the opinion of the investigator, is likely to interfere with completion of the study will be excluded.\n\nFor Part A (Cross-sectional Study of PAP Syndrome)\n\n* Individuals that do not have a diagnosis of PAP\n\nFor Part B (Longitudinal \\& PRO Survey Study of autoimmune PAP Patients)\n\n* Individuals that do not have a diagnosis of autoimmune PAP","ALL",{"count":16,"type":17},500,"ESTIMATED","5 Years","OBSERVATIONAL","The major goal of Part A of this study is to establish a National PAP Registry to help make reliable new research tests available to doctors to improve the diagnosis of PAP, increase awareness and knowledge of PAP, and give patients a 'seat at the table' in planning and conducting PAP research including the clinical testing of several new potential therapies. The major goal of Part B of this study is to define the natural history of autoimmune PAP (aPAP), develop a disease severity score that reflects how aPAP patients feel and function, and to develop and test novel tools to measure the severity of aPAP lung disease. Funding Source - FDA OOPD",[22],"Pulmonary Alveolar Proteinosis",[24,25,26],"Pulmonary Surfactant","Rare Lung Disease","Registry","RECRUITING","2026-03-16",{"date":30,"type":31},"2026-03-17","ACTUAL",{"date":33,"type":4},"2015-04",{"date":35,"type":17},"2030-12",{"name":37,"class":38},"Children's Hospital Medical Center, Cincinnati","OTHER",1,{"id":41,"slug":4,"hasResults":10,"nctId":42,"briefTitle":43,"officialTitle":44,"acronym":45,"eligibilityCriteria":46,"healthyVolunteers":10,"sex":14,"minAge":47,"maxAge":48,"enrollmentInfo":49,"targetDuration":4,"studyType":51,"phases":52,"briefSummary":54,"conditions":55,"keywords":4,"overallStatus":56,"whyStopped":4,"lastUpdateSubmitDate":57,"lastUpdatePostDateStruct":58,"startDateStruct":60,"completionDateStruct":62,"leadSponsor":64,"locationsCount":4},"100592123","NCT06989333","Local Spraying of GM-CSF Via Bronchoscopy in the Treatment of Autoimmune Pulmonary Alveolar Proteinosis","A Single-arm Clinical Study of Local Spraying of GM-CSF Via Bronchoscopy in the Treatment of Autoimmune Pulmonary Alveolar Proteinosis","aPAP and GMCSF","Inclusion Criteria:\n\n1. Age: 18 to 60 years old;\n2. A clear diagnosis of aPAP must meet at least one of the following diagnostic criteria:\n\n1\\) BALF appears \"milky white\"; Or cytological examination reveals a large amount of PAS-positive protein deposition; 2) HRCT shows typical \"paving stone-like changes\"; 3) Positive for serum GM-CSF antibody. 3. There are more than one of the following treatment indications: Symptoms such as progressive breathing difficulties, coughing, and shortness of breath after activity occur; 2) Without oxygen inhalation, PaO2 \\> 65 mmHg 3) Pulmonary function DLCO accounts for % of the predicted value, ranging from 60% to 80%, including the critical value.\n\n4\\. No other PAP specific treatments (such as WLL, inhaled GM-CSF, biological agents, etc.) have been received recently (for more than 4 weeks).\n\n5\\. Agree to participate in this study and sign the informed consent form.\n\nExclusion Criteria:\n\n1. Secondary PAP (such as secondary to blood diseases, etc.);\n2. Patients with obvious pulmonary fibrosis, emphysema or irreversible lung function impairment;\n3. Patients in the acute exacerbation stage;\n4. Patients with other lung diseases (such as active pulmonary tuberculosis, bronchiectasis with purulent infection or other chronic infections; Have severe asthma, chronic bronchospasm, etc.\n5. Have a history of allergy to GM-CSF antibodies or related drug components;\n6. Patients who have participated in other clinical drug trials within the past three months;\n7. Patients who have experienced severe complications related to bronchoscopy or are intolerant to bronchoscopy;\n8. Concurrent with other serious cardiovascular and cerebrovascular diseases, hematological disorders, malignant tumors, etc.\n9. Pregnant or lactating women.","18 Years","80 Years",{"count":50,"type":17},10,"INTERVENTIONAL",[53],"PHASE2","This study aims to explore a new therapeutic approach: the feasibility, safety and preliminary efficacy of directly spraying GM-CSF into the airway through bronchoscopy for the treatment of aPAP.",[22],"NOT_YET_RECRUITING","2025-05-17",{"date":59,"type":31},"2025-05-25",{"date":61,"type":17},"2025-07-01",{"date":63,"type":17},"2027-06-30",{"name":65,"class":38},"Jiuwu Bai",{"id":67,"slug":4,"hasResults":10,"nctId":68,"briefTitle":69,"officialTitle":70,"acronym":71,"eligibilityCriteria":72,"healthyVolunteers":10,"sex":14,"minAge":4,"maxAge":4,"enrollmentInfo":73,"targetDuration":75,"studyType":19,"phases":4,"briefSummary":76,"conditions":77,"keywords":83,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":85,"lastUpdatePostDateStruct":86,"startDateStruct":88,"completionDateStruct":90,"leadSponsor":92,"locationsCount":5},"100274490","NCT02852928","European Management Platform for Childhood Interstitial Lung Diseases - chILD-EU Register and Biobank","Orphans Unite: chILD Better Together - European Management Platform for Childhood Interstitial Lung Diseases \u002F chILD-EU - International Register and Biobank for Children´s Interstital Lung Disease","chILD-EU","Inclusion Criteria:\n\n* all children with suspected or\n* verified diagnosis of ILD or\n* masquerading as ILD and\n* those with rare localized parenchymal lung diseases\n\nExclusion Criteria:\n\n* other indication as inclusion criteria",{"count":74,"type":17},1000,"10 Years","Generation of a common European database and biobank Continous assessment and implementation of guidelines and treatment protocols Establishment of a large observational cohort of chILD patients Determination the value of outcomes used in child Assess treatment variations used, deliver data from defined protocols and linked outcomes",[78,22,79,80,81,82],"Lung Diseases, Interstitial","Pulmonary Eosinophilia","Pulmonary Fibrosis","Respiratory Distress Syndrome, Newborn","Child",[84],"ILD; chILD","2022-09-18",{"date":87,"type":31},"2022-09-21",{"date":89,"type":31},"2013-12",{"date":91,"type":17},"2029-12",{"name":93,"class":38},"Matthias Griese",""]